Important notice regarding Inveltys

Posted in Latest News on August 7, 2019.

Important notice regarding Inveltys:

The board approved Inveltys (loteprednol etabonate ophthalmic suspension) 1% for addition to Rule 64B13-18.002. Effective August 5, 2019, Licensees are now permitted to prescribe Inveltys.



More Latest News

Board Website Re-Design Survey
November 15, 2023

MQA is planning to revamp the board websites. Please take the survey to give us your recommendations by clicking the survey icon below. Survey closing Friday, 2/2/2024 at 4:30 PM ET Continue reading


Announcing the FY 2022-23 Annual Report and Long-Range Plan
November 1, 2023

An annual publication showcasing trends and information about Florida’s health care regulatory landscape. Continue reading